Associate professor of surgery @UniVerona - Pancreatic surgeon @PancreasVerona
Verona, Italy
Joined January 2012
- Tweets625
- Following811
- Followers1.6K
- Likes399
It did happen🎉@PALACROSeu has the potential to shape the future of pancreatic surgery! Thanks to @MarcBesselink and @ThomasHankMD for co-leadership, thanks to @SalviaRobi for continued mentorship, thanks to @ga3lion and @DenaZade ❤️ for making it possible! @HorizonEU @UniVerona
What a honor to coordinate a 10-million euros project on locally advanced pancreatic cancer with @amsterdamumc and @surgery_hps, funded by the @HorizonEU! @PALACROSeu will establish harmonised standards and expand access to specialised pancreatic surgery. univrmagazine.it/2026/07/07/…
PACT-21 CASSANDRA ph3 RCT, in @TheLancet
❗️Neoadjuvant PAXG is superior to mFOLFIRINOX in R/BR PDAC
❗️EFS is a meaningful and increasingly accepted primary outcome metric
❗️Similar toxicity profile
❗️The 🇮🇹 community, including patient advocacies, is 💪
thelancet.com/journals/lance…
Giuseppe Malleo retweeted
Surgery-specific antimicrobial stewardship programs with personalized antibiotic strategies represent a promising approach to minimizing infection risk while combating antibiotic resistance in procedures such as pancreatoduodenectomy. journals.lww.com/annalsofsur…
First phase 3 RCT demonstrating superiority of a chemotherapy regimen (PAXG over mFOLFIRINOX) in the neoadjuvant setting for resectable and BR PDAC. Primary endpoint ➡️1yr-EFS✅, waiting for mature OS data. 🇮🇹 effort led by @SanRaffaeleMI, funded by patient advocacies.
🇮🇹CASSANDRA TRIAL🇮🇹
Phase 3 RCT: Neoadjuvant PAXG vs mFOLFIRINOX in resectable/BR #PDAC
💥PAXG shows:
✅⬆️EFS
✅⬆️Path response
✅Suggestion of ⬆️OS
✅Same toxicity
PAXG superior to mFOLFIRINOX?
@IHPBA @EurPancClub @EAHPBA @OncoAlert @OfficialPCA @Oncoinfo_it @hpb_so
See you tomorrow 18:00 CET! 🤖
📢 Happening this week. Join the IHPBA Early Career Group Webinar: Minimally Invasive HPB Surgery: From Theory to Practice! 🎤Don't miss out! ✅
🗓 Date: Thursday, 27, March
⏰ Time: 18:00 CET
🔗 Register here: bit.ly/ECGMiSWebinar
#IHPBA #HPBSurgery #ECG
✌️Proud of being part of this wonderful research group‼️A relevant step ahead on a long way to go: unraveling the intricacies of PDAC biology @vincorbo @SalviaRobi @CLuchini10 @BottonChampPanc @AndreaSottoriva @Valsecchifdn @PanCAN @Run4Purple @AISP_Pancreas @P_C_E_ @letswinpc
🚨🚨Out in @Nature, led by @vincorbo: ecDNA is a major source of high-level focal amplification in key oncogenes and a major contributor of MYC heterogeneity in PDAC. MYC dosage affects cell morphology and
dependence on stromal niche factors.
nature.com/articles/s41586-0…
Thank you @TFStoop for putting this together🤩 great int’l collaboration under the @EAHPBA umbrella 💪
As I work in one of the best regional systems, I cannot neglect the sad reality of this editorial. Big effort needed at a national level to improve 🇮🇹🇮🇹The Italian health data system is broken - The Lancet Regional Health – Europe thelancet.com/journals/lanep… @MinisteroSalute
Giuseppe Malleo retweeted
Great honor to welcome @gimalleo in Heidelberg for grand rounds 🙏
Discussing complexity in patient stratification and therapy sequencing sharing the same philosophy 👌🏻
Looking forward to future HD X Verona collaboration 💥🇪🇺
@PancreasVerona
@cw_michalski
@ThomasHankMD
What a blast 💥 it’s been to visit @surgery_hps! An outstanding team of surgeons and a warm hospitality. And exchange of ideas and lots of projects for the future✌️@cw_michalski MartinLoos @Mo_Saeedi_Surg @ThomasHankMD @HenrikNien @bkinnykoester @PancreasVerona @TondatoSusanna
Comprehensive pathologic review of post-neoadjuvant pancreatectomy specimens identified 10 morphologic subtypes, which correlate with survival. Also, intratumor spatial heterogeneity is associated with bad prognosis.
🔥off the press in the @AnnalsofSurgery
Not all PDACs are created equal! The morphologic subtype and intratumor spatial heterogeneity are associated with relevant prognostic implications in post-neoadjuvant pancreatectomy. journals.lww.com/annalsofsur…
Most viewed in the 7 last days 🤩 Happy this paper gained interest! Working on global validation 📆@StefanoCrippa6 @Aicep4
Most viewed in the last 7 days from @JAMASurgery:
What are the rates and factors associated with a futile up-front pancreatectomy in patients with anatomically resectable pancreatic ductal adenocarcinoma?
ja.ma/4fwrsAC
Syst review and meta-analysis of 2 RCTs (including our PANDORINA trial) and 6 NCS with a total of 3.610 patients undergoing distal pancreatectomy ➡️ No-drain policy associated with better postop outcomes❗️Who is still draining ❓journals.lww.com/internation… @MarcBesselink @EAHPBA
Simple clinical parameters (ASA class, tumor size and serum Ca 19.9) help predict futile upfront pancreatectomy in resectable PDAC. Quantitative risk estimation (online calculator) + simplified dichotomous criteria. Not a perfect model, no fancy biomarkers, but pragmatic stuff.
🚨The MetroPancreas model can help predict a futile upfront resection for PDAC (death or recurrence within 6mo) and select parients for neoadjuvant strategies using simple clinical parameters. Check it out ➡️ jamanetwork.com/journals/jam… Online calculator ➡️ aicep.website/metropancreas/
🔥🔥 hot off the press in the @AnnalsofSurgery
🫸 Chasing neck margin to obtain R0 in post-neoadjuvant PD does not translate into improved outcomes
⚠️Positive neck margin associated with non-mitigable prognostic factors, including other margin involvement, and N+ disease
Do you check pancreatic neck margin for frozen section in post-neoadjuvant PD❓In our new paper with @SanRaffaeleMI + @MGHSurgery, conversion of an initially positive neck margin by additional resection was not associated with improved outcomes. journals.lww.com/annalsofsur…
